SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as the community rallies to maintain visibility and momentum while working through technical ticker issues on platform aggregators. Holders are actively coordinating on social channels to foster organic growth and build a long-term community project focused on sustainability and transparency.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently the focal point of intense market debate as investors weigh a recent FSD approval in the Netherlands against persistent concerns over shrinking margins and potential demand issues. While bulls point to vertical integration and future autonomous breakthroughs as long-term catalysts, the community is actively divided between those hunting for a major short squeeze and others bracing for further downside amid ongoing regulatory scrutiny.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate the impact of agentic AI competition against the company's strong fundamentals and established enterprise role. While the community remains polarized by recent volatility and technical support levels, many are focused on the upcoming product showcase as a potential catalyst to shift the narrative and challenge short interest.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community eagerly awaits the official reveal of the ES9 luxury SUV, which many expect to be a major catalyst for future growth and market share expansion. Investors are actively discussing the company's aggressive technological push and strong delivery momentum, fueling intense debate over potential institutional rotation and the ongoing battle between long-term bulls and short sellers.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently experiencing intense volatility fueled by a high-profile endorsement from President Donald Trump, which has clashed directly with ongoing bearish sentiment and short-selling campaigns led by prominent investors like Michael Burry. The community is deeply polarized, with active discussions focusing on the company's long-term defense contracts and AI infrastructure potential versus concerns over its valuation and competitive threats from emerging AI platforms.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is experiencing intense volatility following strong quarterly earnings that showcased solid revenue growth and increased customer adoption, yet the stock remains under pressure as investors weigh these fundamentals against sector-wide concerns regarding AI disruption and SaaS valuation resets. The community is actively debating whether the current sell-off represents an attractive buying opportunity for long-term growth or a structural repricing of high-multiple software companies facing increased competitive threats.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending due to a major multi-year compute deal with Anthropic and an expanded capacity agreement with Meta, which have energized investor interest in the stock. While these partnerships highlight CoreWeave's role as a critical AI infrastructure provider, the community is actively debating the impact of a concurrent debt offering, weighing the massive growth potential against the implications of ongoing corporate dilution.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon is seeing significant market activity as investors react to a speculative but widely discussed 12-billion-dollar acquisition rumor involving Sun Pharma. While the company's substantial debt load and history of recurring takeover chatter are fueling skepticism among some, others are drawn to the stock's potential for a significant valuation reset if a deal materializes.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is currently experiencing extreme volatility and intense debate, with bulls citing a successful turnaround strategy and AI-driven edge demand while bears emphasize overvaluation and historical technical gaps. The stock has become a primary battleground for traders, with heavy discussion focused on its rapid ascent, frequent short-squeeze patterns, and skepticism regarding whether the recent price action is fueled by sustainable momentum or algorithmic distribution.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is facing significant selling pressure amid a broader software sector rotation, fueled by a UBS downgrade and market-wide concerns that AI disruption may commoditize traditional IT enterprise platforms. While the community remains deeply divided between those viewing the decline as a rare value opportunity for a long-term enterprise staple and those warning of a structural breakdown in SaaS valuation models, heavy volume and RSI levels have many traders actively debating whether a capitulation bottom is finally forming.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Travere Therapeutics (NASDAQ:TVTX)  Shares Down 7.8%   - Should You Sell?

Travere Therapeutics (NASDAQ:TVTX) Shares Down 7.8% - Here's What Happened...

<ul class="summary-bullets"><li>The FDA had extended the review of its supplemental New Drug Application for Filspari in January 2026.</li><li>Citi kept a $48 price target for Travere, adding that it expects the FDA to approve the drug.</li><li>If approved, Filspari would become the first treatment specifically indicated for FSGS, a rare kidney disorder.</li></ul>Shares of Travere Therapeutics (TVTX) and Ligand Pharmaceuticals (LGND) are drawing increased investor attention ahead of a key U.S. Food and Drug Administration decision on Filspari, a treatment for a rare kidney disease, expected on April 13.Ligand has a licensing agreement with Travere for Sparsentan, sold under the Filspari brand, under which Ligand will receive milestone payments and a 9% royalty on future global net sales of the drug.At the time of writing, <a href="https://stocktwits.com/symbol/TVTX">TVTX</a> and <a href="https://stocktwits.com/symbol/LGND">LGND</a> shares were little changed in pre-market trading on Friday.<h2 class="st-heading-2">FDA Did Not Seek Additional Information On Safety And Manufacturing</h2>In January, Travere Therapeutics announced that the FDA extended the review of its supplemental New Drug Application (sNDA) for Filspari in focal segmental glomerulosclerosis (FSGS), setting a Prescription Drug User Fee Act (PDUFA) target action date of April 13, 2026. The FDA did not request any additional information related to the drug’s safety or manufacturing.A PDUFA date is the FDA’s target date for making a decision on a drug application, which allows the drug to be marketed in the U.S.If approved, Filspari would become the first treatment specifically indicated for FSGS, a rare kidney disorder that can lead to progressive loss of kidney function and eventual kidney failure. Filspari is an oral, non-immunosuppressive therapy.<h2 class="st-heading-2">Citi Expects FDA Approval</h2>Last month, Citi maintained Travere Therapeutics’ ‘Buy’ rating and $48 price target. The firm expects the FDA to approve Filspari and added that the current share price does not fully reflect the company’s opportunity in FSGS.Travere’s Phase 3 study met its interim goal for proteinuria reduction but did not meet the primary kidney function endpoint. However, longer-term results showed the drug improved proteinuria, remission rates, and reduced progression to kidney failure, while remaining well-tolerated. Proteinuria is the high concentration of protein, usually albumin, in urine.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits was ‘bullish’ for TVTX and ‘neutral’ for LGND.One user expects TVTX stock to decline if there is no update before Friday’s close.<stembedurl>https://stocktwits.com/Smellmahass/message/649764886</stembedurl>However, another user expected a pre-FDA run-up to $32 - $35.<stembedurl>https://stocktwits.com/Buckeyeboy722/message/649091978</stembedurl>Year-to-date, TVTX shares have declined 20% while LGND stock has gained around 5%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Travere Therapeutics, Ligand In Focus As FDA Set To Rule On Filspari Next Week – First FSGS Drug At Stake 

The FDA is expected to announce its decision on Filspari, a drug to treat focal segmental glomerulosclerosis, a type of kidney ailment.

TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari

Equity

Travere Therapeutics (NASDAQ:TVTX) Director Sells $330,000.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) Director Roy Baynes sold 10,000 shares of the business's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $33.00, for a total transaction of $330,000.00. Following the transaction, the director owned...

Aberdeen Group plc Trims Holdings in Travere Therapeutics, Inc. $TVTX

Aberdeen Group plc trimmed its position in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 46.4% in the 4th quarter, according to the company in its most recent disclosure with the...

Travere Therapeutics (NASDAQ:TVTX) Shares Up 7.7% - Still a Buy?

Travere Therapeutics (NASDAQ:TVTX) Trading 7.7% Higher - Should You Buy...

Palisades Investment Partners LLC Invests $5.26 Million in Travere Therapeutics, Inc. $TVTX

Palisades Investment Partners LLC purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities...

Travere Therapeutics (NASDAQ:TVTX) Insider Sells $300,000.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Elizabeth Reed sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold...

Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 60,000 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric Dube sold 60,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price...

Hennion & Walsh Asset Management Inc. Increases Position in Travere Therapeutics, Inc. $TVTX

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 169.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 99,229 shares of the company's stock aft...

Tudor Investment Corp ET AL Cuts Stake in Travere Therapeutics, Inc. $TVTX

Tudor Investment Corp ET AL cut its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 52.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 95,747 shares of the company's stock after s...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Current Price	$28.96
Prev Close	$31.44
Open	$31.25
Dividend Yield	0.00%
50-Day Moving Average	$29.37
Beta	1.51
Avg. Volume	1.25M
PE Ratio	-52.14

52-Week High	$42.13
52-Week Low	$13.14
Market Capitalization	$2.9B
EPS (Annual)	-$0.5634
Price to Book	24.89
Revenue Per Employee	$987,380.28

TVTX
Travere Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TVTX News

TVTXTravere Therapeutics Inc